

Thermo Fisher Announces \$3.5 Billion Acquisition of Phadia

2011-05-20

Longtime WilmerHale client Thermo Fisher Scientific Inc. announced that it has signed a definitive agreement to acquire Phadia—a Sweden-based company that develops, manufactures and markets complete blood-test systems to support the clinical diagnosis and monitoring of allergy and autoimmune diseases—from European private equity firm Cinven. The deal is valued at approximately \$3.5 billion in cash and is expected to be completed in the fourth quarter of 2011. Thermo Fisher, a Waltham, Massachusetts-based company, will incorporate Phadia as part of its Specialty Diagnostics business within its Analytical Technologies Segment.

Partner [Hal Leibowitz](#), chair of WilmerHale's Corporate Group, led the team advising Thermo Fisher on the acquisition. Other members of the WilmerHale team included Partners [Christian Crones](#), [Jeffrey A. Hermanson](#), Tim Matthews, [Lester Ross](#), Sven Volcker and [Kenneth Zhou](#); Counsel [Cormac O'Daly](#), Jerry Marr and David Morris; Senior Associates Lisa Arsenidou, Elizabeth Black, Suzy Byron, Stefan Eggert, Aileen Gao and Alison Kapilow; and Associates Philippe Claessens, Christina Frangos, Franziska Irmer, Frederik Rother and Franziska von Kummer. A press release explaining this transaction in greater detail is available on [Thermo Fisher's website](#).